BLFS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 222.22
- PEG ratio
- 65.38
- P/B
- 4.13
- P/S (TTM)
- 16.69
- EV/EBITDA
- 322.00
Profitability & growth
- ROE (TTM)
- 12.8%
- Operating margin
- 6.0%
- Revenue growth YoY
- 21.5%
- Dividend yield
- —
- Beta
- 1.92
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About BioLife Solutions Inc
Company profileBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3303 MONTE VILLA PARKWAY, BOTHELL, WA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
